Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the pathophysiological mechanism of omalizumab in
patients with documented chronic urticaria who have complaints under standard antihistamine
treatment. With this study the investigators will assess the correlation between Fc-IgE
receptor downregulation as well as functionality and clinical response to omalizumab
treatment in patients with chronic urticaria. This may be an approach for other diseases as
well, where Fc-IgE receptor crosslinking are essential. The treatment time is set for a total
of 4 monthly applications of omalizumab. According to the dosage recommendations of recent
studies, fixed doses of 300 mg omalizumab are administered subcutaneously.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborators:
Adverse Drug Reactions, Advice and Consulting ADR-AC Novartis University of Bern